Global Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2016-2021)
|出版商||Mordor Intelligence LLP||商品編碼||367215|
|全球抗病毒藥物市場預測:市場規模、區分、市場佔有率、競爭情形 Global Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2016-2021)|
|出版日期: 2016年01月01日||內容資訊: 英文||
In the year 2015, the Global Anti-Viral drugs market was valued at USD XX Million. It is expected to increase to an estimated market value of USD XX Million while growing at a CAGR of XX.X% during the forecast period. Anti-Viral drugs are the drugs used to treat viral infections which can range from infections like flu to AIDS (Acquired Immuno Deficiency Syndrome). Just like common cold which is also caused by virus, most viral diseases are extremely difficult to cure and what the anti-viral drugs mostly do is slow down the reproduction of virus which in some cases enables immune system to eliminate the virus (as in case of flu) while slowing down the disease progression in other cases (as in case of AIDS).
The need of anti-viral drugs for patient's lifetime in case of diseases like HIV/AIDS along with well-established supply chain that facilitates easy procurement are driving the growth of this market. While the increasing use of generics along with lack of incentivization and lack of curative anti-viral drugs for indications like HIV/AIDS are hindering the growth of this market.
This market has been segmented on the basis of target disease into HIV/AIDS, Hepatitis, Herpes and Influenza. The market has also been segmented by type of anti-viral into IPR Protected and Generic.
Based on geography, this market has been segmented into North America (United States, Canada and Mexico), Europe (United Kingdom, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (APAC) (China, Japan, India, Australia, South Korea and Rest of APAC), Middle-East and Africa (MEA) (GCC, South Africa and Rest of MEA), South America (Brazil, Argentina and Rest of South America).
Lack of broad spectrum anti-viral drugs is currently the huge unmet need in this market and presents a great opportunity to companies. While the negative impact of viral vaccines on the growth of anti-viral drugs market and increasing focus on prevention rather than cure of viral diseases are currently the challenges faced by this market.
There are several major players operating in this market and some of them include: Abbott, Bristol-Myers-Squibb, Gilead, GlaxoSmithKline, Johnson & Johnson, MedImmune/AstraZeneca, Merck & Co, Roche and Schering-Plough.
XX Commercial in Confidence.